Plant ID: NPO3564
Plant Latin Name: Fraxinus stylosa
Taxonomy Genus: Fraxinus
Taxonomy Family: Oleaceae
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
609233-1
China
TSHR; NMUR2; | |
ADRA2C; ADRA2A; | |
PTPN1; | |
GAA; ACHE; | |
TDP1; HPGD; AKR1B1; GFER; HSD17B10; ALOX15; AKR1B10; ALDH1A1; POLB; | |
MAPK1; | |
CA2; CA1; CA12; CA9; CA13; CA7; CA3; CA14; CA5B; CA5A; CA6; | |
CASP1; CASP7; | |
MMP9; MMP1; MMP2; | |
HIF1A; NFKB1; | |
LMNA; | |
XDH; |
Cytochrome P450 Enzymes: | CYP1A2; |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.849E-10 | 3.661E-07 | CA1, CA12, CA13, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, MMP1, MMP2, MMP9, PTPN1 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.684E-28 | 1.020E-23 | CA1, CA12, CA13, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 1.633E-06 | 1.976E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 6.462E-06 | 5.605E-03 | AKR1B1, AKR1B10, ALDH1A1, ALOX15, CYP1A2, GAA, GFER, HPGD, HSD17B10, XDH |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.054E-05 | 7.651E-03 | HPGD, MMP2, MMP9 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.129E-05 | 7.684E-03 | CA2, CA7 |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.129E-05 | 7.684E-03 | ADRA2A, ADRA2C |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.535E-21 | 2.760E-17 | CA1, CA12, CA13, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.841E-20 | 2.544E-16 | CA1, CA12, CA13, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 3.043E-05 | 1.443E-02 | ADRA2A, CA2, CA9, HPGD, TSHR |
MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 5.625E-05 | 2.187E-02 | CA1, CA2 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.889E-27 | 4.131E-25 | CA12, CA1, CA3, CA5B, CA2, CA5A, CA7, CA6, CA9, CA14, CA13 |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.067E-06 | 7.626E-05 | MMP1, MMP2, MAPK1, MMP9 |
09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 1.222E-05 | 5.826E-04 | CASP7, CASP1, MAPK1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 9.499E-05 | 1.941E-03 | MMP1, MMP2, MAPK1, HIF1A, MMP9, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 5.536E-05 | 1.319E-03 | CASP7, MAPK1, MMP9, NFKB1 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 2.480E-05 | 8.865E-04 | AKR1B10, GAA, AKR1B1 |
09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.411E-04 | 2.464E-03 | CASP7, LMNA, MAPK1, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05134 | Legionellosis | 1.551E-04 | 2.464E-03 | CASP7, CASP1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 5.805E-04 | 6.922E-03 | MMP2, MAPK1, HIF1A, MMP9 |
09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 1.725E-04 | 2.467E-03 | CASP1, MAPK1, NFKB1 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 9.275E-04 | 9.359E-03 | MMP2, MAPK1, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 8.752E-04 | 9.359E-03 | MMP2, MAPK1, MMP9 |
09160 Human Diseases | 09167 Infectious diseases | hsa05132 | Salmonella infection | 5.808E-04 | 6.922E-03 | CASP1, MAPK1, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 9.817E-04 | 9.359E-03 | MAPK1, HIF1A, NFKB1 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 3.503E-05 | 1.002E-03 | CYP1A2, XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MMP9; MMP2; CA9; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; ACHE; MMP9; MMP2; CA9; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |